Detalhe da pesquisa
1.
Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial.
Lancet Oncol
; 17(7): 976-983, 2016 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-27267608